Omalizumab as add‐on therapy in a patient with severe asthma and OSA

Omalizumab as add‐on therapy in a patient with severe asthma and OSA

Obstructive sleep apnoea (OSA) syndrome, the most frequent sleep‐disordered breathing, is a comorbidity of asthma, whose prevalence covers about 49.5% of asthmatic adult patients. A 61‐year‐old female patient, affected by severe allergic asthma and obesity, started treatment with omalizumab and unde...

Full description

Bibliographic Details
Main Authors: Giulia Scioscia, Enrico Buonamico, Maria Pia Foschino Barbaro, Donato Lacedonia, Roberto Sabato, Giovanna Elisiana Carpagnano
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Respirology Case Reports
Subjects:
Biological therapy
lung function
obstructive sleep apnoea
polysomnography
severe asthma
Online Access:https://doi.org/10.1002/rcr2.518

Internet

https://doi.org/10.1002/rcr2.518

Similar Items